^
Association details:
| Biomarker: | FGFR2 amplification |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Excerpt:
...- HR+ HER2- breast cancer harboring an FGFR2 gene amplification....
Trial ID:
Source:
Title:
A study to evaluate the effects of TAS-120 in patients with Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
Excerpt:
...HR+ HER2- breast cancer harboring an FGFR2 gene amplification. ...
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy and safety of futibatinib in patients with locally advanced/metastatic triplenegative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study
Published date:
12/02/2023
Excerpt:
Overall, 2 patients had a confirmed partial response (ORR: 9.5%; 95% confidence interval [CI]: 1.2, 30.4), with a median DOR of 6.1 months (range: 3.1−9.2 months). Five (23.8%) patients had stable disease....In heavily pretreated patients with metastatic TNBC harboring FGFR2 gene amplification, futibatinib monotherapy demonstrated modest anticancer activity.
Trial ID:
